

**NATIONAL INSTITUTE FOR HEALTH AND CARE
EXCELLENCE**

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

**STA Pembrolizumab for treating relapsed or refractory
classical Hodgkin lymphoma [ID1062]**

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Consultation

1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how?

No equality issues were raised during the scoping process.

2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these?

No equality issues were raised in the submissions, expert statements or academic report.

3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these?

No equality issues were identified by the committee.

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other

groups? If so, what are the barriers to, or difficulties with, access for the specific group?
No

5. Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?
No

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?
Not applicable

7. Have the committee's considerations of equality issues been described in the appraisal consultation document, and, if so, where?
Not applicable

Approved by Associate Director (name): ...Janet Robertson.....

Date: 27 February 2018

Final appraisal determination

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the committee addressed these?

In their consultation response, the NCRI-ACP-RCP commented, in reference to people with Hodgkin lymphoma who cannot have a stem cell transplant (population 2), that:

“There is also an equity issue here. Currently people in that group either die, or they crowd fund for the drug, or they fund for it privately. Not everyone can do this so a negative decision will inevitably lead to a disparity based on wealth and ability to mount a social media campaign.”

The committee did not consider this to be an equality issue that could be addressed in its decision making. Considerations of the ability of people to pay for treatments privately does not override the committee’s duty to take into account the relative costs and benefits of the interventions when deciding whether it should be recommended or not.

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No

3. If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No

4. If the recommendations have changed after consultation, are there any recommendations or explanations that the committee could make

to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?

Not applicable

5. Have the committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?

Not applicable

Approved by Associate Director (name): ...Janet Robertson.....

Date: 15 June 2018